HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Both in vivo and in vitro studies have shown that inhibition of HSD17B13 expression is beneficial for the treatment of NAFLD/NASH and is one of the emerging potential targets for NAFLD/NASH.